Clinical Trial Update: An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial [EARLY_Phase 1]

View source ↗

Summary

The EARLY Phase 1 ENLIGHTEN trial is evaluating rhPSMA-7.3 PET/CT imaging to detect biochemically recurrent prostate cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• rhPSMA-7.3 PET/CT (rhPSMA-7.3)

Snippet

Sponsor: Northwestern University | Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | EARLY_Phase 1 | Status: RECRUITING